Motif Bio Appoints Dr. Thomas M. File To Its Scientific Advisory Board

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Dr. Thomas M. File to its Scientific Advisory Board. Currently, Dr. File, a renowned expert in infectious diseases, Chairs the Division of Infectious Diseases at Summa Health System, Akron, Ohio, is Professor of Internal Medicine and Master Teacher, and the Chair of the Infectious Disease Section of Northeast Ohio Medical University (NEOMED).

Dr. File is a highly respected and internationally recognized expert on infectious diseases including skin and skin structure infections (SSSIs) and pneumonia. Previously, Dr. File served as Past-President and as a member of the Board of Directors for the National Foundation for Infectious Diseases and on the Board of Directors for the Infectious Disease Society of America. In 2010, he was elected as a Faculty Member to the Alpha Omega Alpha Honorary Society and in 2013, was recipient of the Watanakunakorn Clinician Award of the Infectious Diseases Society of America.

Over the last 38 years, Dr. File has published over 275 original papers and numerous review articles and delivered some 145 presentations on various aspects of infectious diseases at scientific meetings throughout the USA and internationally. He currently, serves on the Editorial Boards of Infectious Diseases in Clinical Practice, where he is Editor-in-Chief; Infectious Disease News; plus the Journal of Microbiology and Immunology and Infection.

Dr. David Huang, Chief Medical Officer at Motif Bio plc, commented: "We are very pleased to welcome Dr. Tom File to our team of scientific experts. Dr. File's extensive clinical and research knowledge in infectious diseases, especially in the management and treatment of SSSIs and pneumonia, will provide critical expert input into the clinical development of our anti-bacterial programmes for serious and life threatening conditions."

Enquiries

For further information please contact

Motif Bio plc [email protected] Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)
+44 (0) 207 533 7727
Phil Walker / John Treacey
Dominic Wilson

Northland Capital Partners Limited (Broker)
+44 (0) 20 7382 1100
Gerry Beaney/David Hignell
John Howes/Mark Treharne (Broking)

Plumtree Capital Limited (Financial Advisor)
+44 (0) 207 183 2493
Stephen Austin

MC Services AG (Public Relations)
Raimund Gabriel
+49 (0) 89 210 2280
Shaun Brown
+44 (0) 207 148 5998

Yellow Jersey PR Limited (Investor Relations)
+44 (0) 7768 537 739
Dominic Barretto
Fiona Walker

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus ) and MDRSP (multi-drug resistant Streptococcus pneumoniae ) that have become prevalent in patients in both the community and hospital settings.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.